Summary
Although the effectiveness of influenza vaccination is established, vaccination policies and their implementation differ considerably across Europe. Historically, the selective policies for influenza vaccination were based on the proven efficacy of influenza vaccine in healthy volunteers, and recognition that influenza complications and death occur mostly in elderly people with chronic medical conditions. Healthcare providers are faced with increasingly aging populations and costly new technologies and are more likely to extend immunisation policies if new initiatives are cost effective compared with accepted measures. Few studies of vaccine effectiveness focus on elderly cohorts with and without high risk conditions. Accordingly, healthcare providers in Denmark, Sweden, The Netherlands and the UK may require further data on vaccine effectiveness in elderly people without high risk conditions before reconsidering their policies. Scandinavian countries may also require data demonstrating benefits in people with diabetes. Review of recent US studies indicates that the available data on vaccine effectiveness in preventing influenza-related hospitalisation and death are applicable in Europe, but vaccine costs and cost effectiveness, and the overall economic burden of inpatient and outpatient care, need to be assessed country by country.
Similar content being viewed by others
References
Fedson DS, Hannoun C, Leese J, et al. Influenza vaccination in 18 developed countries, 1980-1992. Vaccine 1995; 13: 623–7
Nicholson KG, Snacken R, Palache AM. Influenza immunization policies in Europe and the United States. Vaccine 1995; 13: 365–9
Curwen M, Dunnell K, Ashley J. Hidden influenza deaths. BMJ 1990; 300: 896
Sprenger MJW, Mulder PGH, Beyer WEP, et al. Impact of influenza on mortality in relation to age and underlying disease, 1967-1989. Int J Epidemiol 1993; 22: 334–40
Glezan WP, Couch RB. Influenza viruses. In: Evans AS, editor. Viral infections of humans: epidemiology and control. 3rd ed. New York: Plenum, 1989; 419–49
Sullivan KM, Monto AS, Longini IM. Estimates of the US health impact of influenza. Am J Pub Health 1993; 83: 1712–6
Govaert ME, Thijs CTMCN, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals. JAMA 1994; 272: 1661–5
Ahmed AH, Nicholson KG, Nguyen Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989–90 epidemic. Lancet 1995; 346: 591–5
Fleming DM, Watson JM, Nicholas S, et al. Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989/90 using a general practice database. Epidemiol Infect. In press
Perez-Tirse J, Gross PA. Review of cost–benefit analyses of influenza vaccine. Pharmacoeconomics 1992; 2: 198–206
Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost–effectiveness in a health maintenance organisation. Ann Intern Med 1994; 121: 947–52
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nicholson, K.G. Socioeconomics of Influenza and Influenza Vaccination in Europe. Pharmacoeconomics 9 (Suppl 3), 75–78 (1996). https://doi.org/10.2165/00019053-199600093-00017
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199600093-00017